US 12,433,846 B2
Drug delivery system for treatment of cancer
Yrr Morch, Trondheim (NO); Ruth Schmid, Tiller (NO); Einar Sulheim, Trondheim (NO); Per Stenstad, Trondheim (NO); Heidi Johnsen, Trondheim (NO); Kjersti Flatmark, Blommenholm (NO); and Karianne Giller Fleten, Oslo (NO)
Assigned to SINTEF TTO AS, Trondheim (NO); and Oslo Universitetssykehus HF, Oslo (NO)
Filed by SINTEF TTO AS, Trondheim (NO); and Oslo Universitetssykehus HF, Oslo (NO)
Filed on Sep. 24, 2021, as Appl. No. 17/484,725.
Application 17/484,725 is a continuation of application No. PCT/EP2019/076121, filed on Sep. 26, 2019.
Application 17/484,725 is a continuation of application No. 16/366,596, filed on Mar. 27, 2019, granted, now 11,806,330.
Prior Publication US 2022/0257525 A1, Aug. 18, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/51 (2006.01); A61K 31/337 (2006.01); B82Y 5/00 (2011.01)
CPC A61K 9/5153 (2013.01) [A61K 9/5192 (2013.01); A61K 31/337 (2013.01); B82Y 5/00 (2013.01)] 11 Claims
 
1. A method for treatment of cancer in a subject, the method comprising intraperitoneally administering to the subject a poly(alkyl cyanoacrylate) nanoparticle, the nanoparticle encapsulating a hydrophobic anti-cancer drug, and wherein the nanoparticle is administered to the subject to treat the cancer in the subject, wherein the poly(alkyl cyanoacrylate) comprises a cyanoacrylate having a 2-ethyl butyl (EBCA) alkyl chain, wherein the nanoparticle does not include a targeting moiety, and wherein the cancer is a primary peritoneal cancer or peritoneal carcinomatosis.